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Abstract 
The assessment of patterns of patentability in plant biotechnology on the basis of existing 
statistics shows a considerable concentration of patents to a few countries, in particular the United 
States, Australia, Japan, China, Mexico, Brazil, Germany, Canada, New Zealand, South Korea, India, 
Spain and Hungary. These patterns suggest that there is a clear relationship between the choice of 
patent jurisdictions and the biotechnology regulatory framework. This observation of the 
geographic distribution of biotechnology patents lends credence to maintaining a system of 
territorial rights that allow for regulatory competition, but continuing the process of substantive 
patent law harmonization which potentially minimize trade barriers, 
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Premier en date en nos jardins potagers, après la fève d'abord 
et plus tard le pois, le chou était tenu en haute estime par 
l'Antiquité classique ; mais il remonte bien plus haut, à tel point 
que tout souvenir s'est perdu concernant son acquisition. 
L'histoire ne s'occupe guère de ces détails ; elle célèbre les 
champs de bataille qui nous tuent, elle garde le silence sur les 
champs de culture qui nous font vivre ; elle sait les bâtards des 
rois, elle ne sait pas l'origine du froment. Ainsi le veut la sottise 
humaine. 
Jean Henri Fabre ‘Souvenirs Entomologiques’ (1823 -1915) 
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I. Introduction 
Intellectual property protection and the patent system are based upon the principle of 
territoriality and independence. Despite an extensive amount of harmonization in treaty law, 
in particular the Paris Convention and the TRIPs Agreement, as well prominently the 
European Patent System, titles of protection essentially pertain to domestic law and thus may 
vary from country to country. In a globalizing economy, the quest for uniform and single 
patent titles, harmonization and cooperation in registration has been advanced for good 
reasons: legal security, reducing costs and efficiency.1 The last century saw the entry into 
force, inter alia, of the Patent Cooperation Treaty (PCT), the European Patent Convention 
(EPC), the Euroasean Patent Convention (EAPO), the African Regional Intellectual Property 
Organization (ARIPO), the African Intellectual Property Organization (OAPI), and several 
attempts at the World Intellectual Property Organization (WIPO) sponsored Patent Law 
Treaty (PLT) without a concluded agreement. A recent increment in these efforts was in 2010 
when the Cooperative Patent Classification project (CPC) was launched between the USPTO 
and the EPO. This event was preceded by the IP5 initiative between the USPTO, EPO, JPO, 
SIPO, and KIPO which aims at avoiding work duplication in database management, patent 
classification and examiner training in 2008.2 In addition, under the umbrella of PCT-Patent 
Prosecution Highway (PCT-PPH) a number of bilateral agreements between patent offices 
have been signed that enable patent applicants to request a fast-track examination procedure 
where examiners can make use of the work products from the other offices.3 
Efforts in substantive harmonization within the European Union have led the path in a 
regional context. They witnessed, for many years, great difficulties in bringing about a single 
patent with comprehensive geographical coverage of all the 27 Member States: issues of 
languages and translation, and issues of judicial review suitable not only for EU members, but 
also other contracting parties of the EPO. The current developments in the unification of 
European patent law also do not seem to add to the reduction of cost, simplification or 
streamlining of the system.4 Difficulties abound. The more so, this is true on a global scale. A 
global patent may streamline the system of rules and procedures and eliminate parallel 
duplicate or redundant searches and procedures, but that too awaits proof. It may support 
innovation more than a decentralised system, however that is also contested.5 Yet, it is unclear 
                                                
1 MN Meller, ‘Planning For a Global Patent System’, Journal of the Patent and 
Trademark Office Society vol. 80, 1998, pp. 379-391. 
2 See the web brochure at : http://www.epo.org/papers/classification-ip5/index.html and 
http://www.fiveipoffices.org/  (accessed 11.6.2012) 
3 See the list of such agreements maintained by the WIPO : 
http://www.wipo.int/pct/en/filing/pct_pph.html (accessed 22.6.2012); note that there are 
also a number of PPH agreements which do not include PCT work products. The first 
pilot PCT-PPH started on January 29, 2010 and involved the Trilateral Offices : EPO, 
JPO and USPTO. 
4 See Jaeger, T, All Back to Square One? - An Assessment of the Latest Proposals for a 
Patent and Court for the Internal Market and Possible Alternatives, 2012, 
<http://papers.ssrn.com/abstract=1973518>; Ullrich, H, Harmonizing Patent Law: The 
Untamable Union Patent, 2012, <http://papers.ssrn.com/abstract=2027920>. 
5 For arguments that distinguish unjustifiable and unjustified in the context of 
intellectual property rights, and the proposal that « intellectual property law, in general, 
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at this point in time whether differences in legal culture, levels of social and economic 
development and thus diverging interests encourage or discourage the advent of a global 
patent law, or if its advantages in terms of efficiency will be able to cope with the challenges 
of equity involved.6 In assessing pros and cons, much depends upon assessing past and 
current patterns of patenting around the globe. The broader coverage can be observed, the 
stronger a case for a global patent system and indeed global law beyond the TRIPs Agreement 
can be made. Vice-versa, the stronger we observe diversity and uneven distributions of 
patents sought, the less a case for global patents can be made. Observations and answers may 
vary from sector to sector. At this stage, it would seem that a comprehensive view is not yet 
established and in sight.  
In this paper we look at the patent application patterns for plant biotechnology patents, We are 
interested in clarifying whether the need for a uniform global patent7 or patent system8 is born 
out by patenting patterns in this particular field of technology. We chose to address this sector 
because this is one area of technology where markets, consumer perceptions and preferences, 
as well as regulatory environments have been well studied. Plant and animal biotechnology 
offer technological solutions for many of the health9 and resource-based10 problems facing the 
world, thus these remain of central importance in a globalized economy.11 Plant 
biotechnology patents12 find their implementation in two main sectors: industrial agriculture 
                                                                                                                                                   
should be sunsetted » see Johnson, EE, Intellectual Property and the Incentive Fallacy, 
<http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1746343>. Florida State 
University Law Review, forthcoming, at 52. 
6 JH Barton, ‘Issues Posed by a World Patent System’, Journal of International 
Economic Law vol. 7, no. 2, 2004, pp. 341-357. 
7For the purpose of this paper a ‘global patent’ is a single title specification with 
universal effect (legal). 
8 A ‘global patent system’ includes the global patent and the organizations that issue, 
administer and adjudicate matters pertaining to it. 
9 For example:AM Pohlit, NP Lopes, RA Gama, WP Tadei, & VF Neto, ‘Patent 
literature on mosquito repellent inventions which contain plant essential oils--a review.’, 
Planta Medica vol. 77, no. 6, 2011, pp. 598-617; SA Wilson, & SC Roberts, ‘Recent 
advances towards development and commercialization of plant cell culture processes for 
the synthesis of biomolecules.’, Plant Biotechnol J vol. 10, no. 3, 2012, pp. 249-268. 
10 For example: UT Bornscheuer, GW Huisman, RJ Kazlauskas, S Lutz, JC Moore, & K 
Robins, ‘Engineering the third wave of biocatalysis.’, Nature vol. 485, no. 7397, 2012, 
pp. 185-194. 
11 ‘The bioeconomy to 2030: Designing a Policy Agenda’, 2009, OECD, pp. 322. at 15 
(Executive Summary). 
12 An example of such a patent application is WO 2007/127206 Biological Systems 
Input-Output : Response Systems and Plant Sentinels, that includes synthetic eukaryotic 
signal transduction pathways, synthetic signal sensitive promoter which would cause 
plants to turn white in colour (de-greening) thus turning the plant into a detector for 
some specified chemical agent. Other examples would be those that deal with 
genetically modified crops and could include biopharming applications, herbicide 
tolerance, pest resistance, agronomic traits, product quality or characteristics, and 
technical traits such as chemical markers which are essential for breeding programmes, 
but have no commercial value for growers. 
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and pharmaceuticals.13 This paper seeks to assess patterns of patenting of biotechnology in 
section II and to square results found with the different regulatory environments encountered 
in different countries in section III. We do not address issues raised by the use of plant genetic 
resources14 or any biodiversity concerns. We also do not address issues relating to the 
production of new plant varieties using biotechnology methods that may be eligible for 
protection under the International Union for the Protection of New Varieties of Plants 
(UPOV) regime. In section IV we conclude that our data suggests that the world of plant 
biotechnology lends support to the thesis that patent law exhibits strong reasons for 
maintaining diversity between states, and that the case for a global patent or the unification of 
patent laws remains unsupported by our considerations of plant biotechnology.15 
 
II. Patent Priority Statistics for Plant Biotechnology 
The current global patent system has been labelled as one of ‘labyrinths and catacombs’ 
because it is riddled by rules and procedures that are in principle harmonized, but that are by 
far not streamlined.16 In addition, the mix (plant variety, patent, utility patent, plant patent) 
and scope of intellectual property protection for plant biotechnology subject matter varies 
across jurisdictions.17 An applicant seeking patent protection has five options depending on 
which procedural option is chosen. Often the most frequent option is to file nationally first 
(resident filing), and then within the twelve months of priority pursue additional routes 
towards non-resident patent application. There are four possibilities within the Paris 
Convention members and non-members, Patent Cooperation Treaty and European patent 
Convention member states, all with harmonized, but not identical procedures and deadlines.  
                                                
13 For a practitioner’s perspective on biotechnology inventions see: Grubb, PW, & PR 
Thomsen, Patents for Chemicals, Pharmaceuticals and Biotechnology: Fundamentals of 
Global Law, Practice and Strategy, 5 edn., Oxford University Press, USA, 2010. at 274-
300. 
14 Within the context of the International Treaty for Plant Genetic Resources for Food 
and Agriculture adopted by the Conference of the Food and Agriculture Organization of 
the United Nations (FAO) on 3 November 2001 in Rome, ‘plant genetic resources’ 
means genetic material of plant origin where ‘genetic material’ means any material of 
plant origin, including reproductive and vegetative propagating material, containing 
functional units of heredity. In broad terms, plant genetic resources issues have to do 
with whole genetic functional units of hereditary, plant varieties, biodiversity and 
conservation of genomes.  
15 Stack, A, International Patent Law: Cooperation, Harmonization and an Institutional 
Analysis of WIPO and the WTO, Edward Elgar Pub, 2011. at 157. 
16 Drahos, P, The Global Governance of Knowledge: Patent Offices and their Clients, 
Cambridge University Press, 2010. at 55-90. 
17 KA Sechley, & H Schroeder, ‘Intellectual property protection of plant biotechnology 
inventions’, Trends in Biotechnology vol. 20, no. 11, pp. 456-461; M Llewelyn, ‘From 
‘outmoded impediment’ to global player: the evolution of plant variety rights’ in D 
Vaver, & L Bently (eds.), Intellectual Property in the New Millennium: Essays in 
Honour of William R. Cornish, Cambridge University Press, 2004, pp. 137-156. 
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A. Patent	  Statistics:	  Methods	  Used	  1. Data	  Structure	  and	  Search	  Strategy	  
For purposes of this investigation the EPODOC18 database has been used to generate an initial 
data set using the IPC19 patent classes identified in Annex A.20  In the EPODOC database 
113’638 patents were identified. This initial data set was further restricted to a subset of 
45’783 patents containing (in bibliographic data) the keywords in Annex B. This subset of 
selected patents in EPODOC corresponds to 20’337 patent families in the Derwent World 
Patent Index database (DWPI)21. Using patent families affords the advantage of dealing with 
single inventions instead of individual patents in various jurisdictions. DWPI uses priority 
data to group patents into families; a subsequent patent application may have more than one 
priority but this is not very frequent. Simple statistics on this data subset were generated using 
patent families in DWPI and displayed in the figures below where the number of documents 
in each of the jurisdictions or origins is visualized. No time restrictions have been applied to 
the searches. 22  
In order to check the accuracy rate of the selected IPC classes (as refined through the selected 
keywords), the contents of a sample of 991 EPODOC patent documents was inspected. This 
has shown that a total of 870 patent documents were dealing with plants where 803 of them 
belonged to the field of plant genetics (81%). Patent applications are published after 18 
months following the first filing date (priority date). Subsequent applications in other 
countries are not published after 18 months, but in most cases only after being granted, thus 
several years may elapse before these show up in any database. This depends on the specific 
rules in a country and on the local examination procedure in general. Thus a cut-off date 
allowing for the 18 months delay in publication is not sufficient to assure that all members of 
a patent family are included in the subset.23 
                                                
18 EPODOC is the EPO’s worldwide bibliographic database used for prior art searches. 
The country coverage of the database is in Annex D ; it includes the two letter country 
codes. 
19 The International Patent Classification (IPC) established in 1971 (Strasbourg 
Agreement) provides for a hierarchical system of language independent symbols for the 
classification of patents and utility models according to the different areas of technology 
to which they pertain; see http://www.wipo.int/classifications/ipc/en/.  
20 This has been made available by the Swiss Federal Institute of Intellectual Property, 
Berne, Switzerland (June 2011; November 2011) and accessed by Heinz Müller; the 
data discussed was generated 15.11.2011. 
21 DWPI coverage: <http://scientific.thomson.com/support/patents/coverage/> . 
22 Search executed 15.11.2011 at the Swiss Federal Institute for Intellectual Property by 
Heinz Müller. 
23 This difficulty is also acknowledged in the OECD Patent Statistics Manual which 
states that, at all offices, there is a processing and examination time, which can be very 
lengthy in some cases. As a consequence, statistics based on granted patents only are 
not strictly comparable across patent offices owing to the variability in the time needed 
to grant a patent in each patent office. In addition, as patent offices have faced a surge 
of their workload since the mid-1990s, the grant delays have increased, so that “the 
number of grants would reflect the underlying dynamics only in a smoothed and 
delayed manner (‘calendar effect’)” oecd.org, ‘OECD Patent Statistics Manual’, 2009,  
at 64. 
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2. Results	  
A total of 21’208 patent families were retrieved from DWPI following the search criteria in 
Annexes A and B in EPODOC.24  From this total, 11’000 families have US priority. This 
amounts to almost 50% of all inventions in plant genetic resources in this database which 
originate in the US. The terms of art to distinguish between national applications and foreign 
one are resident and non-resident applications (or granted patents) based on the priority. 
Residency of a patent is determined relative to the county or entity code assigned to its 
priority (CH for Switzerland, CN for China, WO for PCT routed applications, etc.).25  a) Relative	  Number	  of	  Filings	  for	  USA	  (US),	  China	  (CN),	  Japan	  (JP),	  South	  
Korea	  (KR),	  Australia	  (AU),	  Great	  Britain	  (GB),	  Germany	  (DE),	  and	  France	  
(FR)	  
 
In Figure 1 a selection from the total data set of 21’208 families representing priorities 
according to initial registration entity is displayed. Of note is that the US priorities 
account for almost 50 per cent of the total, followed by China and Japan. The PCT (WO) 
and the EPC (EP) routes are taken by ca. 5 per cent of the applicants and account only for 
a total 10 per cent of the total. The y-axis in this and all subsequent figures corresponds 
to the number of documents in the subset. Note that Figure 1 does not display a complete 
list of all jurisdictions on the x-axis, just a selection of the more frequent ones. 
 
                                                
24 A sample of 991 documents from the initial EPODOC set was verified for accuracy 
and 81% of these were found to correctly correspond to inventions in plant genetics. 
This is significant when considering absolute numbers, but irrelevant when examining 
trends.  
25 Country codes are standardized ; the various standards, recommendations and 
guidelines in use can be downloaded at: 
http://www.wipo.int/standards/en/part_03_standards.html#group-b (16.11.2011). 
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b) National	  and	  International	  Applications	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In Figure 2 the proportion of national versus international filings is displayed. Filings where 
the priority and patent number are identical (PR=PN) are resident filing in the country or 
origin (national filings). Of significance is that 55 per cent of all US applications are used as 
priority for subsequent filings in other jurisdictions either through the PCT, EPC or by any of 
the other available routes. This in marked contrast with SIPO (CN) original filings where less 
than five per cent are also subsequently filed abroad (non-resident applications). PCT and 
EPC filings are by definition (multilateral conventions) destined for subsequent filings in the 
jurisdictions of its member states and are thus automatically international. 
We recognize two kinds of behaviours that depend on the origin of the initial (priority) filing. 
One is represented by the US, GB, DE, FR all of which see a majority of their national filings 
follow some international route(s) towards building a patent family for the invention. The 
second kind of behaviour represented by CN, JP, and KR exhibits a domination of the 
national patent, and only a small fraction of the domestic filings are chosen to cover other 
markets. One can say that what is invented in China, stays in China, and what is invented in 
the US, goes out into the world. There are many plausible explanations for these patterns that 
could be used to understand the behaviours. One possible explanation is that Chinese firms 
and inventors are mostly concerned with their original market and place of production, and 
are not keen on strong patent protection in the rest of the world, while is the US looks to 
protect both its knowledge and commercial markets. 
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c) PCT	  Filings	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Of the 1261 documents in the data set, 1133 were published as WO documents (application, 
search report, etc.). That not all documents with WO priorities are published as WO 
documents is not surprising as some of these may have gone through the EPC-PCT route 
claiming the priority, but before publication the PCT process was dropped once the priority 
had been claimed.  
In this figure we also observe that majority of patent filings for the subset representing plant 
biotechnology seek protection in the USA, Australia, Japan, China, Mexico, Brazil, Germany, 
Canada, New Zealand, South Korea, India, Hungary, South Africa and Spain. All state 
designations below Spain (ES) have less than 100 documents (less than 10 per cent of the 
original 1261 documents represented in this graph). 
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d) EPC	  Fillings	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In Figure 4, the destination distribution of the 1103 documents with an EPC priority is shown. 
It shows that the majority of the applications entering the patent system through this route are 
destined are routed through the PCT system. A majority of these applicants then seek patent 
protection in the US, Australia, Japan, Germany, China, Canada, Mexico, Brazil, India, Spain, 
South Africa, South Korea, Hungary, and New Zealand (62/1103). One explanation for the 
DE documents with EP priority could be that these were also filed at the German Patent 
Office, or that these correspond to DE utility models or publications of the translation of the 
EP application to German. More than 90 per cent of the EP filings at the EPO or one of its 
national intake office also have a corresponding PCT (WO) document thus representing the 
so-called EP-PCT route. This data does not allow the separation of documents according to 
which route was used. That is a AU document could have been obtained directly through a 
national filing using a foreign priority or through a PCT filing. 
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e) USPTO	  (US)	  Priority	  Filings	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In Figure 5 the filing pattern of the US priority filings is displayed. About 50 per cent of these 
filings are followed with a PCT application. The preferred jurisdictions for patent protection 
for those US priority filings are Australia, Japan, Canada, China, Mexico, Brazil, Germany, 
India, South Africa, South Korea, New Zealand, Spain, Hungary, and to a lesser degree, Israel, 
Norway, Russian and Taiwan. 
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f) China	  (CN)	  Priority	  Documents	  
 
 
 
 
 
 
 
 
 
 
 
 
 
The distribution in Figure 5 shows that the vast majority of CN applications never go beyond 
the original resident application to seek international protection as seen in Figure 2. Of these 
the major markets sought for protection are the US, Australia, Japan, Canada, India, Germany, 
Brazil, Mexico, Korea, New Zealand, and Spain. All other jurisdictions have a number of 
applications below 10 
 
 
  
0	  
500	  
1000	  
1500	  
2000	  
2500	  
3000	  
3500	  
CN	   WO	   US	   AU	   EP	   JP	   CA	   IN	   DE	   BR	   MX	   KR	   ZA	   ES	   HU	   RU	  
3412	  
150	   80	   69	   62	   37	   29	   26	   23	   19	   18	   17	   13	   12	   6	   6	  
 15 
g) Germany	  (DE)	  Priority	  Filings	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In Figure 7 the fate of the DE priority applications displays a preference for markets in 
Australia, United States, Japan, China, Spain, Canada, Brazil, Hungary, Mexico, South Africa, 
South Korea, India, Czech Republic, Norway, Russia, New Zealand, and Israel.  
 3. Patenting	  Patterns	  for	  Plant	  Biotechnology	  
In summary the data above reveals the following patterns for plant biotechnology: 
i.)  More than 50 per cent of all patent families in the data set originate in the US. 
Second ranked are China and Japan with roughly 10 per cent each. In the EU the 
UK, Germany and France only contribute a small fraction of the originating 
patents in this data set.  
ii.)  US and European patent applicants have a majority of international 
applications while China, Japan and South Korea only take a small fraction of their 
inventions abroad.  
iii.)  The majority of international patent filings (EPC and PCT) seek protection in 
the US, Australia, Japan, China, Mexico, Brazil, Germany, Canada, New Zealand, 
South Korea, India, Spain and Hungary. 
The limitations of the data set are given by the coverage in the databases. In particular least 
developed countries and developing countries are underrepresented in DWPI; from the 
African continent only South Africa is represented (Annex E.1).  
The WIPO offers a breakdown of the 2008 PCT national phase entry data by patent office and 
country of origin reveals the ‘flow of patents’ between countries. Here one learns that the 
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EPO received the largest number of national phase entries (83,576), most of which originated 
from the US (33.1%), followed by Japan (14.5%) and Germany (14.4%). Applicants from 
Japan and US filed approximately 55% of all national phase entries at the SIPO (Chinese 
patent office).26 That is, China sees a large influx of non-resident patent applications, and a 
very small outflow of resident inventions, a trend that our results mirror. 
In addition, the WIPO database also offers a breakdown of the statistical analysis by field of 
technology which can be used to further cement or refute arguments relevant to the issue of a 
global patent system. Of note is that patent applications in the life sciences (analysis of 
biological materials and biotechnology) experienced a decline from 2003 to 2007.27  
The trends in the ratios of resident to non-resident patent applications for plant genetic 
resources deserves mentioning. In summary, one can say that industrialized nations have a 
propensity towards applying for non-resident patent protection in territories which may be of 
significance either for production or market reasons. Thus the US resident applicants engage 
to a large extent in non-resident patent application activities through the various routes while 
developing economies such as China find it important to secure protection of their own 
inventions primarily within their own resident territory. This is to be contrasted with the 
observation that high and middle income countries tend to have a higher proportion of 
resident  patent applications, while low income countries show a propensity towards having a 
large proportion of non-resident patent applications.28 Again, our data set reflects the same 
pattern. What appears like China’s attitude of ‘what gets invented in China, stays in China’ 
reflects the overall pattern of CIPO patent applications. In 2011, China with 293,066 resident 
applications displaced Japan (with 290,081) to become the top country for resident 
applications.29  
III. Usage and the Regulatory Environment of Biotechnology and 
Genetically Modified Crops 
A. Global	  Commercialization	  	  
According to Clive James’ report30 countries that grew more than 50,000 hectares of biotech 
crops in 2010 are USA, Brazil, Argentina, India, Canada, China, Paraguay, Pakistan, South 
Africa, Uruguay, Bolivia, Australia, Philippines, Myanmar, Burkina Faso, Mexico, and 
Spain.31 That this list of jurisdictions is not fully reflected by our data set has two possible 
explanations that may apply simultaneously. Firstly, it has to do with of the limitations of the 
database used for extracting the patent families. Secondly, this could be a reflection that some 
                                                
26 WIPO, World Intellectual Property Indicators, 2010 at 58; Available at: 
http://www.wipo.int/ipstats/en/statistics/patents/ 
27 Ibid. at 59. 
28 Ibid. at 41. 
29 WIPO, World Intellectual Property Indicators - 2011 Edition, 
<http://www.wipo.int/ipstats/en/wipi/index.html>. at 6, and 192ff. In contrast, Canada, 
Israel, the Netherlands and Switzerland filed more than 80% of their total applications 
abroad (2011). 
30  http://isaaa.org/ (15.6.2012) 
31 Report available at : http://isaaa.org/resources/publications/pocketk/16/default.asp 
(15.6.2012); unfortunately this report does not include the source of the data reported. 
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of these countries do not have patent systems that are perceived as strong, however this is a 
speculative statement since we are not looking into this aspect.  
While 23 countries planted commercialized biotech crops in 2007, an additional 29 
countries, totalling 52, have granted regulatory approvals for biotech crops for import 
for food and feed use and for release into the environment since 1996. A total of 615 
approvals have been granted for 124 events for 23 crops. Thus, biotech crops are 
accepted for import for food and feed use and for release into the environment in 29 
countries, including major food importing countries like Japan, which do not plant 
biotech crops. 32  
The specific mention of Japan in this context is noteworthy because at the research level 
Japan has seen considerable success albeit through a path different from that taken by the 
US.33 However, Japan has comprehensive regulatory measures in place to guarantee the safe 
handling of GM crop plants that includes a zero tolerance for imports containing GM products 
unapproved by Japan.34 
Of the 52 countries that have granted approvals for biotech crops, Japan tops the list 
followed by USA, Canada, South Korea, Australia, Mexico, the Philippines, New 
Zealand, the European Union and China. Maize has the most events approved (40) 
followed by cotton (18),  canola (15), and soybean (8). The event that has received 
regulatory approval in most countries is herbicide tolerant soybean event GTS-40-3-2 
with 24 approvals (EU=27 counted as 1 approval only), followed by insect resistant 
maize (MON810) and herbicide tolerant maize (NK603) both with 18 approvals, and 
insect resistant cotton (MON531/757/1076) with 16 approvals worldwide.35  
According to the same source 75 per cent of 100 million hectares of soybean planted globally 
in 2011 were biotech (herbicide tolerant) while it accounted for 60% of the world’s soybean 
harvested area in 2005. 36 
The main producer was the US where 87% of the national soybean crop was GM. The 
other major producers of soybean are, based on FAO data, Brazil, Argentina, China 
and India. Gómez- Barbero and Rodríguez-Cerezo (2006a) note that 99% of the 
Argentinean soybean crop was GM in 2005 and that the adoption rate in Brazil was 
also high (data from GMO-Compass37 puts the GM share of Brazilian soybeans at 
64% in 2007). It should be noted that the US, Brazil and Argentina account for 
approximately 90% of world trade in soybeans. China was testing the crop in field 
                                                
32 James, Clive. 2007. Global Status of Commercialized Biotech/GM Crops: 2007. 
ISAAA Brief No. 37. ISAAA: Ithaca, NY.;C James, ‘Global Status of Commercialized 
Biotech/GM Crops: 2007’, ISAAA Brief No 37, 2008, pp. 1-166. at 106. 
33 T Reiss, ‘Success factors for biotechnology: lessons from Japan, Germany and Great 
Britain’, International Journal of Biotechnology vol. 3, no. 1, 2001, pp. 134-156. 
34 J-P Nap, PLJ Metz, M Escaler, & AJ Conner, ‘The release of genetically modified 
crops into the environment. Part I. Overview of current status and regulations’, Plant J 
vol. 33, no. 1, 2003, pp. 1-18. 
35 Supra note 32. 
36 Food Chain Evaluation Consortium (FCEC), ‘Evaluation of the EU legislative framework 
in the field of GM food and feed’, 2010, European Commission: DG SANCO, pp. 1-
238. at 19. 
37 http://www.gmo-compass.org/eng/home/ (30.6.2012) 
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trials in 2005, but does not appear to have introduced GM varieties commercial as 
yet.38  
In agricultural biotechnology a strategy of vertical integration through acquisition and 
consolidation, rather than licensing or contractual agreements for technology use between 
biotechnology, seed and agrochemical firms has been used. 39 This suggests there is 
perception that the patent system does not offer sufficient protection even in jurisdictions with 
the most developed patent traditions. That is, “outright ownership of the knowledge is the sure 
way to protect it.”40 This may be an indication that patent patterns can reflect the perceived 
markets and the presence of competitors, but that for trade purposes commercial actors will 
not rely on the patent system alone to protect their interests.  
B. Diverging	  Regulatory	  Environments	  
The public debate in agricultural biotechnology is fraught with popular misconceptions.41 The 
world is far from uniform standards, and the Carthagena Protocol, negotiated under the 
auspices of the Convention on Biodiversity, is not shared among all nations, in particular with 
the US abstaining. Strongly uneven patterns of use of genetically modified organism focusing 
on a number of countries, in particular the United States, Brazil, Argentina, China, do not 
merely reflect the size of countries and the importance of their agricultural sectors, but also 
the fact of largely diverging regulatory environments. It is not a coincidence that these 
countries offer regulatory regimes favourable to use and commercialization of plant genetic 
resources. The European Union, on the other hand, has been operating restrictions and 
moratoria discouraging recourse to genetically modified organisms.42  
At time of adoption the Directive and Regulation constituted an attempt at a new and 
improved legislative framework governing what had proven to be a difficult area of 
EU policy. Yet, from the time they came into force until March 2010 the EU did not 
adopt a single decision, positive or negative, on an application to cultivate a GMO. 
The Amflora potato is the first cultivation approval in Europe since 1998. Applications 
cycle within the system are stalled, inch forward and then cycle again at the next stage 
of the process. Dissatisfaction and frustration is widespread in all quarters.”43 
In contrast, Japan has both a strict regulatory environment for GMOs and a population who 
                                                
38 Supra note 36 at 19 and references therein. 
39 Isaac, G, Agricultural Biotechnology and Transatlantic Trade: Regulatory Barriers to 
GM Crops, CABI Pub., 2002. at 65. 
40 Ibid. 
41 A McHughen, & R Wager, ‘Popular misconceptions: agricultural biotechnology.’, N 
Biotechnol vol. 27, no. 6, 2010, pp. 724-728. 
42 F Daviter, ‘Schattschneider in Brussels: How Policy Conflict Reshaped the 
Biotechnology Agenda in the European Union’, West European Politics vol. 32, no. 6, 
2009, pp. 1118-1139; C Burns, ‘How and When Did We Get Here? An Historical 
Institutionalist Analysis of EU Biotechnology Policy’, Journal of European Integration 
vol. 34, no. 4, 2012, pp. 341-357. 
43 Conlusion in ‘Evaluation of the EU Legislative Framework in the Field of Cultivation 
of GMOs Under Directive 2001/18/EC and Regulation (EC) No 1829/2003, and the 
Placing on the Market of GMOs as or in Products Under Directive 2001/18/EC’, 2011, 
pp. 1-137. 
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when asked, in general disapproves of biotechnology foods. However the trade figures for 
GMO’s in Japan tell another story:  
Japan remains the world’s largest per capita importer of foods and feeds that have 
been produced using modern biotechnology. Annually Japan imports about 16 million 
metric tons of corn and four million metric tons of soybeans, approximately three 
quarters of which are produced through biotechnology. Japan also imports billions of 
dollars worth of processed foods that contain biotech-derived oils, sugars, yeasts, 
enzymes, and other ingredients.44 
Two reviews, one of the Association of South East Asian Nations (ASEAN),45 and another of 
the Asia Pacific Economic Cooperation (APEC)46 biotechnology regulations identify a broad 
spectrum of regulatory measures and recommend some form of regulatory consolidation 
towards meeting a plethora of goals towards harmonization and to meet the challenges of food 
price volatilities and other fragilities in global food system. Countries regulating 
biotechnology take recourse to different standards of liability. They are instrumental in 
encouraging or discouraging recourse to the technology, and diverging levels of risks assumed. 
Sufian Jusoh47 argues in favour of diverging standards able to take into account the needs and 
preferences of countries. In particular, Jusoh notes that the Kuala Lumpur Supplementary 
protocol allows for such flexibility in the harmonization of the liability rules for 
biotechnology products that it may not contribute to harmonization of liability standards.48 In 
addition, regulatory competition, “may introduce a race to the top, where countries wish to 
protect the environment and the biodiversity whilst at the same time trying to gain advantage 
from the benefits offered by biotechnology.”49 
Similarly, the Committee on Biotechnology of the International Law Association in its interim 
and final report distinguishes the functions of risk assessment and risk management.50 While 
the former should be allocated to international bodies and network of scientific laboratories, 
the later should be left with national government, commensurate with social and economic 
needs and preferences relating to biotechnology. These findings were equally confirmed in the 
doctoral thesis of Michael Burkard.51  
                                                
44 S Sato, ‘Japan Agricultural Biotechnology Annual: Biotechnology Annual Report 
2011’, USDA Foreign Agricultural Service, GAIN Report Number JA1039, 2011, pp. 1-
41. at Executive Summary. 
45 Jusoh, S, Biotechnology Law and Regulation: The ASEAN Perspective, Cameron & 
May, London, 2006. 
46 M Escaler, PPS Teng, & AD Powell, ‘Challenges of Harmonization of Agricultural 
Biotechnology Regulatory Systems across APEC Economies’, Biosafety vol. 1, no. 3, 
2012, pp. 1-7. 
47 Jusoh, S, Harmonisation of Liability Rules in Transboundary Movement of 
Biotechnology Crops, Centre for International Trade and Investment, Kuala Lumpur, 
2012. 
48 Supra note 47 at 273. 
49 Ibid. 
50 T Cottier, & M Footer, ‘International Law on Biotechnology: Final Draft Report and 
Draft Recommendations’, International Law Association, 2010, pp. 1-27. 
51 M Burkard, ‘Risk Assessment and Risk Management in the WTO Agreement on the 
Application of Sanitary and Phytosanitary Measures: Philosophy, Legal Challenges and 
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The interaction between international trade regulation and the issues generated by the 
regulatory environment for biotechnology does not suggest that a ‘one size fits’ all approach 
is recommended. Some aspects require harmonization and others require regulatory 
competition.52 Plant biotechnology skips over the moral and ethical issues associated with 
animal and human biotech, however in the area of intellectual property, plant biotechnology 
may defer/default to the norms otherwise established in the sector where it is being applied. In 
the particular case of plant biotechnology patents, the differentiated pattern of patent activity 
follows the regulatory environment. 
After Monsanto v. Geertson Seed Farms, those who fear GM crops degrading natural 
biodiversity will most likely not prevent deregulation under NEPA. Deregulation 
considerations under the substantial similarity paradigm, are inherently policy decisions 
beyond the jurisdiction of the judiciary. However, the Supreme Court has stated that 
actual contamination would give a farmer standing. Using existing torts, coupled with 
punitive damages, would adequately pressure GM seed distributors to tightly regulate the 
practices and geographic distribution of their end-users. It is only fair that GMO 
intellectual property owners, who have been enforcing their patent rights against 
infringers, should be liable for the adverse consequences of uncontrolled propagation of 
their patented products.”53 
IV. Conclusion and Policy Implications 
The assessment of patterns of patentability on the basis of existing statistics shows a 
considerable concentration of patents to a few countries, in particular the United States, 
Australia, Japan, China, Mexico, Brazil, Germany, Canada, New Zealand, South Korea, India, 
Spain and Hungary. Many least developed and developing countries, mainly due to the 
limitations of the patent statistics, are not included, but it would seem that patenting of 
biotechnology inventions in a majority of countries has not been of interest to industries 
concerned.54 There are many reasons why biotechnology may not be used. Restrictive 
regulatory regimes may be one the most important reasons, but there may be others such as 
size or lack of information and education in the field. But there is a clear relationship between 
the patterns of patenting and the regulatory framework. Countries offering open and 
welcoming regimes attract the bulk of patent applications. Biotechnology industries operating 
in restrictive environments seek protection abroad to secure market access in potentially 
lucrative markets. What can be learned from discussing plant biotechnology patents and their 
geographical distribution is that a global patent automatically encompassing all countries alike 
would not be appropriate and feasible. It would create protection where none is sought and no 
need for protection exist. A global system  as applied to biotechnology (or any other 
                                                                                                                                                   
Future Prospects for Regulation’, Ph D, 2010, World Trade Institute, University of Bern, 
pp. 418.. 
52 S Bibber-Klemm, M Burkhard, S Jusoh, & M Temmerman, ‘Challenges of 
biotechnology in trade regulation’ in T Cottier, & P Delimatsis (eds.), The Prospects of 
International Trade Regulation: From Fragmentation to Coherence, Cambridge 
University Press, 2011, pp. 284-320. 
53 CB Miller, ‘Honey Get My Gun, the Transgenic Seeds Are in the Field Again’, The 
John Marshall Review of Intellectual Property Law 2011, pp. 439-456. 
54 For instance Switzerland, a country with a significant academic effort in 
biotechnology, does not have a significant number of patent documents in the data set 
selected. 
 21 
technology) therefore could be based upon a bundle patent and could be thus be built upon the 
model of the current European Patent Convention (EPC) where one single central 
examination by the EPO serves all the Patent Offices of the member states. Industrial players 
and stakeholders should be able to select countries for which patent protection is sought in a 
one-stop shop approach. Failing the availability of such a one-stop shop, several Patent 
Offices have opted for a bilateral, trilateral or multilateral pragmatic solution with the Patent 
Prosecution Highway (PPH) which so far is more intensively used by applicants filing first at 
the JPO.55 In part, the PPH approach mirrors the EPC approach in that the application is not 
examined several times, thus it reduces not only duplication of work when the patent 
application enters the national phase, but also reduces the time between application and 
subsequent grant of the patent. 
The patterns of patenting, on the other hand, do not exclude the possibility of further 
harmonization in terms of substantive law. To what extent this is feasible depends upon a 
closer analysis of the relationship of patents and the regulatory environment of the technology 
and social and economic needs in accord with Stack’s argument that patent law cannot be 
regarded as merely technical in nature, and that it is inherently political.56 The obvious answer 
to the question of when is international patent law harmonization well founded, is that when 
the trade-offs between diversity and harmonization are optimised, then harmonization is 
justified. In fact, what Stack argues is that “patent law exhibits strong reasons for maintaining 
diversity between states, and that the case for the unification of patent laws is normatively 
unsupported.”57  
Importing and exporting countries will not have the same needs, and developing countries 
may need the benefit of graduation and thus less stringent commitments in order to facilitate 
technology transfer.58 For the time being, we conclude that a single title encompassing all 
countries alike in accordance with single and uniform standards is not matched by the data 
available on patterns of patents in the field.  
                                                
55 World Intellectual Property Indicators 2011, WIPO Economic Statistics Series, Table 
A.13.1 Cumulative number of PHH requests (excluding PCT-PHH requests), February 
2010 to June 2011, and PCT-PHH requests. For the period reported, 3,799 applications 
first filed at the JPO were subsequently filed at the USPTO using this fast-track (at 94). 
For comparison, the JPO received 344,598 (national, resident and non-resident) patent 
applications, and acted as receiving office for 31’523 PCT applications in 2010 (at 193). 
For a discussion see D Chun, ‘Patent Law Harmonization In The Age of Globalization: 
The Necessity and Strategy for a Pragmatic Outcome’, Journal of Patent Trademark 
Office Society vol. 93, no. 2, 2012, pp. 127-166. 
56 15 at 158 ; and for a detailed analysis of the recent determination by the Extended 
Board of Appeal of the European Patent Office that methods for breeding broccoli and 
tomatoes were not patentable where it concludes that the right to patent agricultural 
innovations is increasingly located within a political context see : M Blakeney, 
‘Patenting of plant varieties and plant breeding methods.’, Journal of Experimental 
Botany vol. 63, no. 3, 2012, pp. 1069-1074. 
57 Stack, International Patent Law: Cooperation, Harmonization and an Institutional 
Analysis of WIPO and the WTO. at 157. 
58 See also 6 
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VI. Annexes 
C. IPC	  Classes	  Selected	  (Any)	  
IPC Classes Description 
A01H (2006.01)  SECTION A — HUMAN NECESSITIES 
AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING 
NEW PLANTS OR PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION 
BY TISSUE CULTURE TECHNIQUES 
A61K38/56 (2006.01)  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K 
31/00; cyclic dipeptides not having in their molecule any other peptide link than those 
which form their ring, e.g. piperazine-2,5-diones, A61K 31/00; ergoline-based peptides 
A61K 31/48; containing macromolecular compounds having statistically distributed amino 
acid units A61K 31/74; medicinal preparations containing antigens or antibodies A61K 
39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides 
as drug carriers, A61K 47/00)  
. Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; 
Derivatives thereof 
.. Protease inhibitors 
... from plants 
C07K4/10 (2006.01)  Peptides having up to 20 amino acids in an undefined or only partially defined sequence; 
Derivatives thereof 
. from plants 
C07K14/415 (2006.01)  Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; 
Derivatives thereof 
. from plants 
C07K16/16 (2006.01)  Immunoglobulins, e.g. monoclonal or polyclonal antibodies 
. against material from plants 
C12N5/04 (2006.01)  Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or 
maintenance thereof; Culture media therefor (plant reproduction by tissue culture 
techniques A01H 4/00)  
. Plant cells or tissues 
C12N5/14 (2006.01)  Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or 
maintenance thereof; Culture media therefor (plant reproduction by tissue culture 
techniques A01H 4/00)  
. Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells 
.. Fused cells, e.g. hybridomas 
... Plant cells 
C12N15/05 (2006.01)  Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, 
e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants 
or genetically engineered micro-organisms C12N 1/00, C12N 5/00, C12N 7/00; new 
plants A01H; plant reproduction by tissue culture techniques A01H 4/00; new animals 
A01K 67/00; use of medicinal preparations containing genetic material which is inserted 
into cells of the living body to treat genetic diseases, gene therapy A61K 48/00; peptides 
in general C07K)  
. Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion 
.. Plant cells 
C12N15/29 (2006.01)  Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, 
e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants 
or genetically engineered micro-organisms C12N 1/00, C12N 5/00, C12N 7/00; new 
plants A01H; plant reproduction by tissue culture techniques A01H 4/00; new animals 
A01K 67/00; use of medicinal preparations containing genetic material which is inserted 
into cells of the living body to treat genetic diseases, gene therapy A61K 48/00; peptides 
in general C07K)  
. Recombinant DNA-technology 
.. DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant 
technology C07H 21/00)  
... Genes encoding plant proteins, e.g. thaumatin 
C12N15/82 (2006.01)  Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, 
e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants 
or genetically engineered micro-organisms C12N 1/00, C12N 5/00, C12N 7/00; new 
plants A01H; plant reproduction by tissue culture techniques A01H 4/00; new animals 
A01K 67/00; use of medicinal preparations containing genetic material which is inserted 
into cells of the living body to treat genetic diseases, gene therapy A61K 48/00; peptides 
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IPC Classes Description 
in general C07K)  
. Recombinant DNA-technology 
.. Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; 
Regulation of expression 
... Vectors or expression systems specially adapted for eukaryotic hosts 
.... for plant cells 
 
D. Keywords	  
Gen+ or proteom+ or transgen+ or cysgen+ or epigen+ or nucleotid+ or 
(nucleic_acid) or dna or rdna or cdna or tdna or rna or mran or trna or 
snrna; exon+ or intron+ or allel+ or oncogene+ or genotype+ or qtls or 
transcript+ or phenotyp+ or (cloning_vector+) or (yeast_artifical_chromosome) 
or homozygote+ or heterozygot+; polymorphism+ or recessive or dominant or 
recombinant or silencing or pcr or shotgun or sequenc+ or microarray or rflp 
or rapd or aflp or trflp or dgge or fish or facs or blast or alignement 
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E. Derwent	  World	  Patent	  Index	  Database	  
 1. DWPI	  Coverage59	  
Argentina (1975)*  
Australia (1963-69,1983-pres.)  
Austria (1975-present)  
Belgium (1963-present)  
Brazil (1976-present)  
Canada (1963-present)  
China (1987-present) Czech Republic (1994-present)  
Czechoslovakia (1975-1994)*  
Denmark (1974-present)  
European Pat. Off. (1978-present)  
Finland (1974-present)  
France (1963-present)  
Germany (1963-present)  
Germany (Utility Models) (1995-present)  
German (Dem. Rep.) (1963-1990)  
Hungary (1975-present)  
India (2004-present)  
Ireland (1963-69,1995-pres.)  
Israel (1975-present)  
Italy (1966-69,1978-present)  
Japan (1963-present)  
Luxembourg (1984-present)  
Mexico (1997-present)  
Netherlands (1963-present)  
New Zealand (1993-present)  
Norway (1974-present)  
PCT (WIPO) (1978-present)  
Philippines (1994-present)  
Portugal (1974-present)  
Rep. of Korea (1986-present)  
                                                
59 http://www.cas.org/ASSETS/1050EF3EB1AD43698692C0E3E682A34A/wpids.pdf 
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Romania (1975-present)  
Russian Federation (1994-present)  
Singapore (1995-present)  
Slovakia (1994-present)  
South Africa (1963-present)  
Soviet Union (1963-1994)*  
Spain (1983-present)  
Sweden (1974-present)  
Switzerland (1963-present)  
Taiwan (1993-present)  
United Kingdom (1963-present)  
United States (1963-present)  
Additional Sources are:  
Research Disclosure (1978-present) Copyright: Kenneth Mason Publications Limited 
[2006] www.researchdisclosure.com  
International Technology Disclosures (1984-93)*  
 
* signifies available within the backfile only  
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F. Epodoc	  
Epodoc is a database produced, administered, and updated daily by the European 
Paten Office. which compose the systematically classified search documentation of 
the European Patent Office. The documents consist of published applications, granted 
patents as well as classified non-patent literature (XP documents). The EPODOC 
database essentially corresponds to the DOCdb database which is the internal EPO 
master file used for the management of the search documentation. The bibliographic 
data (i.e. the publication, application and priority numbers and dates, the IPC classes, 
the inventors and applicants data and the title) are available for patent documents of 
most countries or other patent authorities (81 countries in July 2007). 1. Epodoc	  Coverage60	  
1 Albania (AL) 
2 ARIPO (AP) 
3 Argentina (AR) 
4 Austria (AT) 
5 Australia (AU) 
6 Bosnia and Herzegovina (BA) 
7 Belgium (BE) 
8 Bulgaria (BG) 
9 Brazil (BR) 
10 Canada (CA) 
11 Switzerland (CH) 
12 Chile (CL) 
13 China (CN) 
14 Costa Rica (CR) 
15 Czechoslovakia (CS) 
16 Cuba (CU) 
17 Cyprus (CY) 
18 Czech republic (CZ) 
19 German Democratic republic (DD) 
20 Germany (DE) 
21 Denmark (DK) 
22 Algeria (DZ) 
23 Eurasia (EA) 
24 Ecuador (EC) 
                                                
60 Status : July 2011 (EPO). 
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25 Estonia (EE) 
26 Egypt (EG) 
27 European Patent Offi ce (EP) 
28 Spain (ES) 
29 Finland (FI) 
30 France (FR) 
31 Great Britain (GB) 
32 Gulf Cooperation Council (GC) 
33 Georgia (GE) 
34 Greece (GR) 
35 Hong Kong S.A.R (HK) 
36 Croatia (HR) 
37 Hungary (HU) 
38 Indonesia (ID) 
39 Ireland (IE) 
40 Israel (IL) 
41 India(IN) 
42 Iceland (IS) 
43 Italy (IT) 
44 Japan (JP) 
45 Kenya (KE) 
46 Korea (South) (KR) 
47 Liechtenstein (LI) 
48 Lithuania (LT) 
49 Luxembourg (LU) 
50 Latvia (LV) 
51 Morocco (MA) 
52 Monaco (MC) 
53 Moldova (MD) 
54 Republic of Montenegro (ME) 
55 Former Yugoslav Republic of Macedonia (MK) 
56 Mongolia (MN) 
57 Malta (MT) 
58 Malawi (MW) 
59 Mexico (MX) 
 30 
60 Malaysia (MY) 
61 Nicaragua (NI) 
62 Netherlands (NL) 
63 Norway (NO) 
64 New Zealand (NZ) 
65 OAPI (OA) 
66 Panama (PA) 
67 Peru (PE) 
68 The Philippines (PH) 
69 Poland (PL) 
70 Portugal (PT) 
71 Romania (RO) 
72 Republic of Serbia (RS) 
73 Russia (RU) 
74 Sweden (SE) 
75 Singapore (SG) 
76 Slovenia (SI) 
77 Slovakia (SK) 
78 San Marino (SM) 
79 Soviet Union (SU) 
80 El Salvador (SV) 
81 Tajikistan (TJ) 
82 Turkey (TR) 
83 Chinese Taipei (TW) 
84 Ukraine (UA) 
85 United States of America (US) 
86 Uruguay (UY) 
87 Viet Nam (VN) 
88 World Intellectual Property Organization (WO) 
89 Former Serbia and Montenegro (YU) 
90 South Africa (ZA) 
91 Zambia (ZM) 
92 Zimbabwe (ZW) 
 
 
